News & events
| News
AusVaxSafety commences routine surveillance of 2024 seasonal influenza vaccines
| News
Vaccine safety in Australia AusVaxSafety summary report now available
| News
What to expect in the days after your XBB.1.5 COVID-19 vaccine
| News
Shingrix® vaccine safety data now available
| News
AusVaxSafety monitoring monovalent Omicron XBB.1.5 variant COVID-19 vaccine safety
| News
AusVaxSafety commences enhanced surveillance of Shingrix® following addition to the NIP schedule
| News
AusVaxSafety surveillance of 2023 seasonal flu vaccines concludes with no safety issues identified
| News
Vaxtracker wins Hunter New England Health Excellence Award
| News
Subcutaneous and intradermal administration of mpox vaccine well tolerated, AusVaxSafety study finds
| News
New bivalent BA.4/BA.5 COVID-19 booster vaccines well tolerated by Australians, new AusVaxSafety data show
All news & events
| News

AusVaxSafety exceeds 200 SmartVax sites nationwide

AusVaxSafety active vaccine safety surveillance data are provided by SmartVax, Vaxtracker and STARSS. No safety signals have been identified through active surveillance to date. AusVaxSafety active safety surveillance data continue to be updated regularly on the website.

Influenza: From 1 April 2017 to 3 September 2017, 102,663 individuals aged 6 months and older were enrolled for influenza vaccine surveillance. With an over 70% response rate, 73,560 participants consistently replied that any events after vaccination were generally mild and within expected ranges.

Zoster: As of 3 December 2017, a total of 10,739 persons aged 70–79 years have participated in zoster surveillance since 1 November 2016, yielding a response rate of 68%. Pertussis: As of 10 December 2017, 29,592 children aged 12 months–<7 years have participated in pertussis surveillance since 14 March 2016, yielding a response rate of 72.4%. As of 4 December 2017, there are 201 SmartVax sites nationwide. A live map can now be accessed on the SmartVax website.